Sema4 Holdings Corp. Provides Earnings Guidance for the Second Half and Full Year 2022
For the full year, the company expects revenue to be $245 million - $255 million, reflecting the inclusion of GeneDx's results for the eight months of ownership in 2022. Embedded in this revenue guidance is a $24 million reduction in revenue due to estimated change of Sema4's revenue related to periods prior to 2022 and a more conservative outlook on volumes and pricing trends within reproductive health product lines for the remainder of the year.